Clinical case of complete response of metastatic colorectal cancer to immunotherapy

Metastatic colorectal cancer with microsatellite instability (MSI) occurs in approximately 5 % of cases, which is significantly lower than in localized stages (15 %). MSI leads to the accumulation of a large number of mutations and neoantigens on the surface of tumor cells, thereby increasing tumor immunogenicity and determining the efficacy of immune checkpoint inhibitors. According to the results of the KEYNOTE-177 trial, the use of pembrolizumab as first-line therapy for MSI metastatic colorectal cancer statistically significantly increased the median progression-free survival to 16.5 months compared with 8.2 months with standard chemotherapy plus bevacizumab or cetuximab, while grade ≥ 3 adverse events were reported considerably less frequently (22 % vs. 66 %). This article describes a clinical case of a 67-year-old female patient with pT3N2 colon adenocarcinoma (MSI, KRAS G12D mutation, NRAS and BRAF wild-type), in whom disease progression in the form of hepatic and pulmonary metastases was detected one month after completion of 8 cycles of adjuvant chemotherapy according to the XELOX regimen (oxaliplatin + capecitabine). In August 2021, immunotherapy with pembrolizumab 400 mg once every 42 days was initiated. After 12 cycles, complete regression of metastatic lesions in the liver and lungs was achieved. A total of 26 cycles of immunotherapy were administered; in May 2024, given the sustained complete response and a treatment duration exceeding 2.5 years, immunotherapy was discontinued. During the course of treatment, hypothyroidism developed, which was compensated by levothyroxine replacement therapy. According to follow-up examination data from July 2026, the complete response is maintained, the duration of complete response exceeds 3 years, and the treatment-free interval is more than 1.5 years. This case demonstrates the possibility of achieving a durable response to pembrolizumab immunotherapy in patients with MSI metastatic colorectal cancer that is sustained following treatment completion. Further studies aimed at identifying additional predictive biomarkers are needed to optimize the choice between mono- and combination immunotherapy in this category of patients.

Authors

Institutions

Publication Details

Journal
MD-Onco
Published
2026-11-17
DOI
https://doi.org/10.17650/2782-3202-2026-6-3-45-50
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical case of complete response of metastatic colorectal cancer to immunotherapy

D. A. Chekini, N. M. Kutakov
MD-Onco
Cancer Immunotherapy and Biomarkers
article

Clinical case of complete response of metastatic colorectal cancer to immunotherapy

D. A. Chekini, N. M. Kutakov
article en

Abstract

Metastatic colorectal cancer with microsatellite instability (MSI) occurs in approximately 5 % of cases, which is significantly lower than in localized stages (15 %). MSI leads to the accumulation of a large number of mutations and neoantigens on the surface of tumor cells, thereby increasing tumor immunogenicity and determining the efficacy of immune checkpoint inhibitors. According to the results of the KEYNOTE-177 trial, the use of pembrolizumab as first-line therapy for MSI metastatic colorectal cancer statistically significantly increased the median progression-free survival to 16.5 months compared with 8.2 months with standard chemotherapy plus bevacizumab or cetuximab, while grade ≥ 3 adverse events were reported considerably less frequently (22 % vs. 66 %). This article describes a clinical case of a 67-year-old female patient with pT3N2 colon adenocarcinoma (MSI, KRAS G12D mutation, NRAS and BRAF wild-type), in whom disease progression in the form of hepatic and pulmonary metastases was detected one month after completion of 8 cycles of adjuvant chemotherapy according to the XELOX regimen (oxaliplatin + capecitabine). In August 2021, immunotherapy with pembrolizumab 400 mg once every 42 days was initiated. After 12 cycles, complete regression of metastatic lesions in the liver and lungs was achieved. A total of 26 cycles of immunotherapy were administered; in May 2024, given the sustained complete response and a treatment duration exceeding 2.5 years, immunotherapy was discontinued. During the course of treatment, hypothyroidism developed, which was compensated by levothyroxine replacement therapy. According to follow-up examination data from July 2026, the complete response is maintained, the duration of complete response exceeds 3 years, and the treatment-free interval is more than 1.5 years. This case demonstrates the possibility of achieving a durable response to pembrolizumab immunotherapy in patients with MSI metastatic colorectal cancer that is sustained following treatment completion. Further studies aimed at identifying additional predictive biomarkers are needed to optimize the choice between mono- and combination immunotherapy in this category of patients.

MD-OncoVol. 6(3)
Mother Hospital (IN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon